<DOC>
	<DOCNO>NCT01973868</DOCNO>
	<brief_summary>To establish safety , tolerability pharmacokinetics regorafenib cetuximab combination , determine maximum tolerate dose ( MTD ) recommend Phase 2 dose ( RP2D )</brief_summary>
	<brief_title>Safety Pharmacokinetics Regorafenib Cetuximab Combination</brief_title>
	<detailed_description />
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Patients histologically cytologically confirm , locally advanced metastatic solid tumor candidate standard therapy regorafenib cetuximab consider standard treatment . Patients metastatic colorectal cancer ( mCRC ) must record Kras gene mutational analysis available Kras mutation present . Male female patient ≥ 18 year age Women childbearing potential must blood urine pregnancy test perform maximum 7 day start study treatment , negative result must document start study treatment Life expectancy least 3 month Adequate bone marrow , liver renal function assess follow laboratory requirement conduct within 7 day start study treatment : Platelet count ≥ 100,000/cubic millimeter ( mm3 ) , hemoglobin ( Hb ) ≥ 8.5 g/dl , leukocyte count &gt; 3,000/mm3 , absolute neutrophil count ( ANC ) ≥ 1,000/mm3 Total bilirubin ≤ 1.5 x upper limit normal ( ULN ) . Mildly elevate total bilirubin ( &lt; 6 mg/dL ) allow Gilbert 's syndrome document . Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤ 2.5 x ULN ( ≤ 5 x ULN subject liver involvement cancer ) Alkaline phosphatase limit ≤ 2.5 x ULN ( ≤ 5 x ULN subject whose cancer involve liver ) . Amylase lipase ≤ 1.5 x ULN Serum creatinine ≤ 1.5 time ULN creatinine clearance ( CLcr ) ≥ 30 mL/min accord CockroftGault formula Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1 Prior treatment Regorafenib Prior discontinuation cetuximab treatment due toxicity intolerance cetuximab Major surgical procedure , open biopsy , significant traumatic injury within 28 day start study medication Nonhealing wound , ulcer , bone fracture Systemic anticancer therapy within 28 day Patients unable swallow retain oral medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Regorafenib</keyword>
	<keyword>Cetuximab</keyword>
	<keyword>Solid tumor</keyword>
	<keyword>Cancer</keyword>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>